Circassia Pharmaceuticals (LON:CIR)‘s stock had its “buy” rating restated by stock analysts at Peel Hunt in a note issued to investors on Monday, April 1st, ThisIsMoney.Co.Uk reports.
Separately, Royal Bank of Canada cut their price objective on Circassia Pharmaceuticals from GBX 81 ($1.06) to GBX 65 ($0.85) and set a “sector performer” rating for the company in a research report on Thursday, January 24th.
Shares of Circassia Pharmaceuticals stock remained flat at $GBX 29.80 ($0.39) on Monday. The stock had a trading volume of 153,621 shares. The stock has a market capitalization of $111.53 million and a PE ratio of -1.12. Circassia Pharmaceuticals has a 1-year low of GBX 25 ($0.33) and a 1-year high of GBX 98.30 ($1.28).
Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD).
Featured Article: Understanding Average Daily Trade Volume
Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.